J Pediatr Health Care. 2022 May-Jun;36(3):280-285. doi: 10.1016/j.pedhc.2022.01.006. Epub 2022 Jan 31.
The COVID-19 pandemic has impacted the care of countless individuals, including pediatric oncology patients. The initial lack of knowledge about the disease course and implications of infection led to delays in treatment to minimize additional harm. In pediatric oncology, unnecessary delays in chemotherapy or hematopoietic stem cell transplantation may increase the risk of disease relapse. This case report describes one high-risk pediatric oncology patient's clinical course through hematopoietic stem cell transplantation immediately following COVID-19 infection complicated by multisystem inflammatory syndrome in children. The disease course, monitoring, long-term outcome, and recommendations for future research are reviewed.
COVID-19 大流行对无数人的护理产生了影响，包括儿科肿瘤患者。最初对疾病过程和感染影响的认识不足导致治疗延迟，以尽量减少额外的伤害。在儿科肿瘤学中，化疗或造血干细胞移植的不必要延迟可能会增加疾病复发的风险。本病例报告描述了一名高危儿科肿瘤患者在 COVID-19 感染后立即进行造血干细胞移植的临床过程，该患者感染 COVID-19 后并发儿童多系统炎症综合征。回顾了疾病过程、监测、长期结果和未来研究的建议。
